Syndax Pharmaceuticals to Present at the SITC 31st Annual Scientific Meeting
November 08 2016 - 9:27AM
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we")
(Nasdaq:SNDX), a clinical stage biopharmaceutical company focused
on developing entinostat and SNDX-6352 in multiple cancer
indications, today announced six poster presentations at the
upcoming Society for Immunotherapy in Cancer (SITC) 31st Annual
Scientific Meeting being held November 9–13, 2016 in National
Harbor, Maryland.
The following Syndax-sponsored posters to be
presented include:
Title: Dose escalation/confirmation results of
ENCORE 601, a phase 1b/2 open-label study of entinostat (ENT) in
combination with pembrolizumab (PEMBRO) in patients with non-small
cell lung cancer (NSCLC)Poster Number:
221Date and Time: Friday, November 11 from
12:15–1:30 PM ETTrack: Combinations:
Immunotherapy/ImmunotherapyPresenter: Melissa L.
Johnson, MD
Title: Targeting colony stimulating factor-1
receptor (CSF-1R) with SNDX-6352, a novel anti-CSF-1R targeted
antibodyPoster Number: 421Date and
Time: Friday, November 11 from 12:15–1:30 PM
ETTrack: Tumor
MicroenvironmentPresenter: Peter Ordentlich,
Ph.D
Additional poster presentations highlighting entinostat
include:
Title: Effect of the class I-HDAC inhibitor
entinostat and the pan-HDAC inhibitor vorinostat on peripheral
immune cell subsetsPoster Number: 207Date
and Time: Friday, November 11 from 12:15–1:30 PM
ETTrack: Combinations:
Immunotherapy/ImmunotherapyPresenter: Lauren
Lepone, Ph.D
Title: Modulation of antibody-dependent
cell-mediated cytotoxicity (ADCC) mediated by the anti-PD-L1
antibody avelumab on human lung and prostate carcinoma cell lines
using the HDAC inhibitors vorinostat and entinostatPoster
Number: 212Date and Time: Saturday,
November 12 from 11:45 AM–1:00 PM ETTrack:
Combinations:
Immunotherapy/ImmunotherapyPresenter: Sofia R.
Gameiro, Ph.D
Title: Entinostat sensitized osteosarcoma cells
for cytotoxic effect of natural killer cellsPoster
Number: 198Date and Time: Saturday,
November 12 from 11:45 AM–1:00 PM ETTrack:
Adoptive Cellular TherapyPresenter: Simin
Kiany
Title: A randomized phase II study of
epigenetic therapy with azacitidine and entinostat with concurrent
nivolumab versus nivolumab alone in recurrent metastatic non-small
cell lung cancerPoster Number: 151Date and
Time: Friday, November 11 from 12:15–1:30 PM ET
Track: Clinical Trials in
ProgressPresenter: Kristen A. Marrone, MD
The posters will be on display starting at 12:00 PM ET on
Friday, November 11 and will remain accessible through 8:00 PM ET
on Saturday, November 12. All accepted abstracts will be
accessible via a special supplement published in SITC’s official
journal, the Journal for ImmunoTherapy of
Cancer (JITC).
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical
company focused on developing an innovative pipeline of combination
therapies in multiple cancer indications. Our lead product
candidate, entinostat, which was granted Breakthrough Therapy
designation by the FDA following positive results from our Phase 2b
clinical trial, ENCORE 301, is currently being evaluated in a Phase
3 registration clinical trial for advanced hormone receptor
positive, human epidermal growth factor receptor 2 negative breast
cancer. Syndax is developing entinostat, which has direct effects
on both cancer cells and immune regulatory cells, and SNDX-6352, an
anti-CSF-1R monoclonal antibody, to potentially enhance the body's
immune response on tumors that have shown sensitivity to
immunotherapy. Entinostat is being evaluated as a combination
therapeutic in Phase 1b/2 clinical trials with Merck & Co.,
Inc. for non-small cell lung cancer and melanoma, with Genentech,
Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt,
Germany, for ovarian cancer. SNDX-6352 is expected to begin
clinical trials during the fourth quarter of 2016 and to be
developed to treat a variety of cancers. For more information on
Syndax, please visit www.syndax.com.
Syndax's Cautionary Note on Forward-Looking
Statements.
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "may," "will," "expect," "plan,"
"anticipate," "estimate," "intend," "believe" and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to
identify forward-looking statements. These forward-looking
statements are based on Syndax's expectations and assumptions as of
the date of this press release. Each of these forward-looking
statements involves risks and uncertainties. Actual results may
differ materially from these forward-looking statements.
Forward-looking statements contained in this press release include,
but are not limited to, statements about the progress, timing,
clinical development and scope of clinical trials and the reporting
of clinical data for Syndax's product candidates and the potential
use of SNDX-6352 to treat various cancer indications. Many factors
may cause differences between current expectations and actual
results including unexpected safety or efficacy data observed
during preclinical or clinical studies, clinical trial site
activation or enrollment rates that are lower than expected,
changes in expected or existing competition, changes in the
regulatory environment, failure of Syndax's collaborators to
support or advance collaborations or product candidates and
unexpected litigation or other disputes. Other factors that may
cause Syndax's actual results to differ from those expressed or
implied in the forward-looking statements in this press release are
discussed in Syndax's filings with the U.S. Securities and Exchange
Commission, including the "Risk Factors" sections contained
therein. Except as required by law, Syndax assumes no obligation to
update any forward-looking statements contained herein to reflect
any change in expectations, even as new information becomes
available.
Investor Contacts
Heather Savelle
Argot Partners
heather@argotpartners.com
Tel 646.395.3734
Media Contact
Eliza Schleifstein
Argot Partners
eliza@argotpartners.com
Tel 973.361.1546
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Apr 2024 to May 2024
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From May 2023 to May 2024